Smaller Companies: Gene genius from Amersham
Sunday 01 December 1996
Amersham International, the Tories' first privatisation, has the skills to reap real benefits from the project. The last few years have been a roller coaster ride for group. Spun off originally from the Atomic Energy Authority, it prospered after the 1982 flotation, boosted by its core life sciences division - which supplies radioactive materials for public and private sector laboratories. Later in the decade, however, the boffins lost their way with an expensive effort to develop blood testing kits.
Bill Castell was then drafted in from Wellcome, as group chief executive, to inject some commercial vigour. After disappointing profits growth, the shares have marked time since 1993. The last two sets of half time figures, however, have come in ahead, fuelling renewed hope for the shares.
Amersham's core expertise still revolves around radioactivity. But the star now, which barely existed in the early 1980s, is branded healthcare products. In the latest six months to 30 September, divisional profits grew 139 per cent to pounds 14.1m - half of total operating profits of pounds 28.7m. A com- bination of acquisitions and new licence approvals have made Amersham the world leader in nuclear medicine, with roughly a third of the market.
One of its products, Metastron, is used for the relief of pain caused by secondary bone cancers. But faster growth is being achieved by diagnostic products, in particular Myoview, which enables doctors to monitor heart disease without surgery. In two years Myoview has taken a large chunk of the European and Japanese markets and is showing signs of doing equally well in the $120m a year US market after approval last April.
A notable coup has been a deal with Sumitomo to merge the Japanese giant's nuclear medicine business with Amersham's much smaller operation there. For pounds 106m the group has a 50 per cent stake in Nihon Medi-Physics (NMP), increasing its share of the Japanese nuclear medicine market tenfold to 67 per cent.
Ultimately the hope is that NMP will use Amersham's global network to gain worldwide distribution for its products.
Looking vigorous, too, is life sciences. Amersham has been improving the non-radioactive side of the business, based on luminescent products, and targeting drugs companies rather than public sector bodies.
At the same time it has been increasing its capabilities in genetic studies. This September, Amersham and bigger rivals Roche and Perkins Elmer swept aside complex arguments about patent protection and gave each other free access to all markets with royalties payable when one of the three is selling the other's product. The effect is to quadruple, to $240m, the market which Amersham can address with its new gene-sequencing products.
Last but not least are promising drugs in the pipeline, including agents to diagnose Parkinson's disease, Alzheimer's and cancer. One analyst is looking for profits to grow from pounds 50.8m to pounds 66.5m this year, followed by pounds 78.5m. With the shares now priced at 1,091p, that would leave the rating in the mid teens. Good value for a company with developments poised to capture the imagination.
Apple has been hit by complaints about the 1.1GB download
Much-loved cartoon character returns - without Sir David Jason
Liam Neeson's Downton dreams
Matt Smith is set to join cast of the Jane Austen classic - with a twist
Actress to appear in second series of the hugely popular crime drama
- 2 Scottish independence: Learn from Quebec's mistakes and beware of promises. Vote Yes.
- 3 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
- 4 Revealed after 75 years of secrecy: 'Fifi' the glamorous WW2 special agent who tested British spies' resolve
- 5 Have you heard about the film Singapore has banned its people from watching? Well, you have now
Thailand beach murders: Thai PM suggests 'attractive' female tourists cannot expect to be safe wearing bikinis
Scottish independence: Final opinion polls show undecided voters could swing result either way
Scottish independence: Almost half of No voters have felt 'personally threatened' by the Yes campaign
Isis release 'Flames of War' video warning Obama of attacks troops could face in Iraq
Hitler’s former food taster reveals the horrors of the Wolf’s Lair
Daniele Watts: Django Unchained actress detained by Los Angeles police after being mistaken for a prostitute
Scottish independence referendum: A nation divided against itself
The political class is doing what Hitler couldn’t – destroying Britain
Scottish independence: Nationalist leader Jim Sillars threatens pro-union companies with 'day of reckoning' after independence
Portuguese academic says British are 'filthy, violent and drunk'
Scottish independence: David Cameron is becoming the 'George Bush of Britain'
iJobs Money & Business
£70-90,000: Saxton Leigh: Our client a London Market Insurer are seeking a Pro...
£60,000 - £80,000: Saxton Leigh: Our client is an leading Asset Manager based...
£18000 - £23000 per annum + Comission: SThree: The SThree group is a world lea...
£18000 - £23000 per annum + Commission: SThree: Real Staffing are currently lo...